Deficiency of the procoagulant cofactor factor VIII (FVIII) in hemophilia A is routinely treated by protein replacement therapy with plasma-derived or recombinant FVIII. Now, a humanized bispecific antibody has been demonstrated to perform the 'scaffold' function of FVIII and could potentially function as a FVIII substitute as a treatment for this inherited bleeding condition (pages 1570–1574).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
World Federation of Hemophilia. World Federation of Hemophilia Report on the Annual Global Survey 2010. <http://www.wfh.org/en/page.aspx?pid=878> (2010).
Bolton-Maggs, P.H. & Pasi, K.J. Lancet 361, 1801–1809 (2003).
Key, N.S. & Negrier, C. Lancet 370, 439–448 (2007).
Mei, B. et al. Blood 116, 270–279 (2010).
Powell, J.S. et al. Blood 119, 3031–3037 (2012).
Kitazawa, T. et al. Nat. Med. 18, 1570–1574 (2012).
Nilsson, I.M., Berntorp, E., Lofqvist, T. & Pettersson, H. J. Intern. Med. 232, 25–32 (1992).
Manco-Johnson, M.J. et al. N. Engl. J. Med. 357, 535–544 (2007).
Hay, C.R.M. et al. Blood 117, 6367–6370 (2011).
Astermark, J. et al. Blood 109, 546–551 (2007).
Fay, P.J. Blood Rev. 18, 1–15 (2004).
De Groot, A.S. & Moise, L. Curr. Opin. Drug Discov. Devel. 10, 332–340 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Lillicrap, D. A complex substitute: antibody therapy for hemophilia. Nat Med 18, 1460–1461 (2012). https://doi.org/10.1038/nm.2959
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2959